Target intelligence / Profile preview

Host gut mucosa and microbiota

Molecular classification
Other
01

Overview

The host gut mucosa and microbiota represent a complex symbiotic ecosystem consisting of the intestinal epithelial lining, the overlying mucus layer, and trillions of microorganisms including bacteria, fungi, and viruses (Thursby & Juge, 2017, PMID: 28539185). This system plays a critical role in human health by facilitating nutrient absorption, synthesizing essential vitamins like K and B12, and training the host immune system to distinguish between commensal organisms and pathogens (NIH, 2023). The gut microbiota also produces metabolic byproducts, such as short-chain fatty acids (SCFAs), which maintain the integrity of the intestinal barrier and influence systemic physiology through the gut-brain and gut-liver axes (Fan & Pedersen, 2021, PMID: 33199854). Dysregulation of this environment, known as dysbiosis, is linked to numerous conditions including inflammatory bowel disease (IBD), metabolic syndrome, and Clostridioides difficile infection (CDI) (CDC, 2022). Therapeutic interventions, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), aim to restore a healthy microbial balance or enhance the protective functions of the mucosal barrier (FDA, 2022). While targeting this system offers significant therapeutic potential, challenges include the high variability of microbial composition between individuals and the risk of systemic infection in immunocompromised patients (Gupta et al., 2016, PMID: 27107786).

Other names
Gut microbiomeIntestinal microbiotaGut floraGastrointestinal mucosaIntestinal barrierGut-brain axis
02

Mechanism of action

Modulation of microbial composition, restoration of intestinal barrier integrity, competitive inhibition of pathogens, and regulation of mucosal immune cell trafficking.

03

Biological functions

Immune responseMetabolismBarrier functionPathogen defenseSignal transductionVitamin synthesis
04

Disease associations

InfectionInflammationMetabolic diseaseCancerNeurodegenerative diseaseAutoimmune disease
05

Safety considerations

Systemic infection risk (bacteremia)Transfer of antibiotic resistance genesDysbiosisUnintended metabolic or immunological changesVariability in individual response
06

Interacting drugs

Rifaximin

6 more in the full profile.

07

Biomarkers

Fecal calprotectinMicrobial diversity indices (Alpha/Beta diversity)Short-chain fatty acid (SCFA) levelsFirmicutes/Bacteroidetes ratioIntestinal fatty acid-binding protein (I-FABP)

Beyond the preview

Go deeper on Host gut mucosa and microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host gut mucosa and microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call